AAPL345.56-1.55 (-0.45%) ▼|ABBV287.93+1.54 (+0.54%) ▲|ABT102.98-0.12 (-0.12%) ▼|ACN244.04+8.88 (+3.77%) ▲|ADBE246.95-1.41 (-0.57%) ▼|AMAT414.42+18.49 (+4.67%) ▲|AMD569.40+9.14 (+1.63%) ▲|AMGN450.80+2.85 (+0.64%) ▲|AMT181.00-2.83 (-1.54%) ▼|AMZN252.19-0.91 (-0.36%) ▼|AVGO347.69+5.36 (+1.57%) ▲|AXP316.37+3.46 (+1.10%) ▲|BA166.64-1.54 (-0.92%) ▼|BAC50.89+0.21 (+0.41%) ▲|BKNG147.09-3.06 (-2.03%) ▼|BLK1,151.49+15.44 (+1.36%) ▲|BMY60.68-0.87 (-1.41%) ▼|BNY148.30+0.72 (+0.49%) ▲|BRK-B543.91+0.92 (+0.17%) ▲|C123.83+1.14 (+0.93%) ▲|CAT714.36+1.05 (+0.15%) ▲|CL91.56-0.61 (-0.66%) ▼|CMCSA21.67-0.18 (-0.80%) ▼|COF203.88+0.44 (+0.22%) ▲|COP149.96+2.00 (+1.35%) ▲|COST985.89-6.25 (-0.63%) ▼|CRM241.26+0.37 (+0.15%) ▲|CSCO109.94-1.45 (-1.30%) ▼|CVS90.24-0.89 (-0.98%) ▼|CVX231.21+2.98 (+1.31%) ▲|DE639.39-0.19 (-0.03%) ▼|DHR235.51+3.51 (+1.51%) ▲|DIS109.24-0.99 (-0.90%) ▼|DUK123.99-0.82 (-0.65%) ▼|EMR167.23+0.96 (+0.57%) ▲|FDX301.82-5.28 (-1.72%) ▼|GD354.55-0.34 (-0.10%) ▼|GE302.34+4.68 (+1.57%) ▲|GEV883.79-11.29 (-1.26%) ▼|GILD159.55+0.47 (+0.30%) ▲|GM81.30+0.76 (+0.94%) ▲|GOOG320.27+3.44 (+1.09%) ▲|GOOGL323.21+2.63 (+0.82%) ▲|GS921.54+9.77 (+1.07%) ▲|HD318.15-0.35 (-0.11%) ▼|HON219.63+0.82 (+0.37%) ▲|IBM251.93+1.68 (+0.67%) ▲|INTC94.37+0.63 (+0.67%) ▲|INTU328.74+0.29 (+0.09%) ▲|ISRG448.48+2.60 (+0.58%) ▲|JNJ271.63+2.90 (+1.08%) ▲|JPM339.54+3.75 (+1.12%) ▲|KO91.71+0.53 (+0.58%) ▲|LIN508.71+0.06 (+0.01%) ▲|LLY1,289.07+7.16 (+0.56%) ▲|LMT630.70+7.71 (+1.24%) ▲|LOW198.61+0.43 (+0.22%) ▲|LRCX253.16+12.31 (+5.11%) ▲|MA613.22+3.37 (+0.55%) ▲|MCD251.05+1.58 (+0.63%) ▲|MDLZ61.82-0.54 (-0.86%) ▼|MDT95.26+1.31 (+1.39%) ▲|META610.12-10.07 (-1.62%) ▼|MMM172.64+1.06 (+0.62%) ▲|MO73.21-0.28 (-0.38%) ▼|MRK140.47-1.35 (-0.95%) ▼|MS189.53+2.62 (+1.40%) ▲|MSFT526.45-4.88 (-0.92%) ▼|MU967.73+38.97 (+4.20%) ▲|NEE81.23-1.20 (-1.45%) ▼|NFLX61.60-0.93 (-1.48%) ▼|NKE37.24-0.33 (-0.87%) ▼|NOW149.79-5.00 (-3.23%) ▼|NVDA216.57-1.37 (-0.63%) ▼|ORCL129.61-0.93 (-0.71%) ▼|PEP132.65-0.85 (-0.64%) ▼|PFE29.31-0.49 (-1.64%) ▼|PG158.93-0.31 (-0.19%) ▼|PLTR193.43-5.31 (-2.67%) ▼|PM203.24+0.62 (+0.31%) ▲|QCOM180.64-3.53 (-1.92%) ▼|RTX197.45+2.85 (+1.46%) ▲|SBUX104.04+1.00 (+0.97%) ▲|SCHW88.30-1.00 (-1.12%) ▼|SO91.82-0.84 (-0.90%) ▼|SPG211.73-0.55 (-0.26%) ▼|T20.67-0.28 (-1.31%) ▼|TMO707.71+14.69 (+2.12%) ▲|TMUS145.50-1.33 (-0.91%) ▼|TSLA401.93-5.54 (-1.36%) ▼|TXN307.07-1.84 (-0.60%) ▼|UBER65.17-0.61 (-0.92%) ▼|UNH408.29-2.11 (-0.51%) ▼|UNP299.31-0.57 (-0.19%) ▼|UPS104.32-1.78 (-1.67%) ▼|USB59.35-0.39 (-0.65%) ▼|V402.18+0.32 (+0.08%) ▲|VZ43.19-0.75 (-1.70%) ▼|WFC83.94+1.28 (+1.55%) ▲|WMT119.15-0.18 (-0.15%) ▼|XOM182.72+2.81 (+1.56%) ▲|AAPL345.56-1.55 (-0.45%) ▼|ABBV287.93+1.54 (+0.54%) ▲|ABT102.98-0.12 (-0.12%) ▼|ACN244.04+8.88 (+3.77%) ▲|ADBE246.95-1.41 (-0.57%) ▼|AMAT414.42+18.49 (+4.67%) ▲|AMD569.40+9.14 (+1.63%) ▲|AMGN450.80+2.85 (+0.64%) ▲|AMT181.00-2.83 (-1.54%) ▼|AMZN252.19-0.91 (-0.36%) ▼|AVGO347.69+5.36 (+1.57%) ▲|AXP316.37+3.46 (+1.10%) ▲|BA166.64-1.54 (-0.92%) ▼|BAC50.89+0.21 (+0.41%) ▲|BKNG147.09-3.06 (-2.03%) ▼|BLK1,151.49+15.44 (+1.36%) ▲|BMY60.68-0.87 (-1.41%) ▼|BNY148.30+0.72 (+0.49%) ▲|BRK-B543.91+0.92 (+0.17%) ▲|C123.83+1.14 (+0.93%) ▲|CAT714.36+1.05 (+0.15%) ▲|CL91.56-0.61 (-0.66%) ▼|CMCSA21.67-0.18 (-0.80%) ▼|COF203.88+0.44 (+0.22%) ▲|COP149.96+2.00 (+1.35%) ▲|COST985.89-6.25 (-0.63%) ▼|CRM241.26+0.37 (+0.15%) ▲|CSCO109.94-1.45 (-1.30%) ▼|CVS90.24-0.89 (-0.98%) ▼|CVX231.21+2.98 (+1.31%) ▲|DE639.39-0.19 (-0.03%) ▼|DHR235.51+3.51 (+1.51%) ▲|DIS109.24-0.99 (-0.90%) ▼|DUK123.99-0.82 (-0.65%) ▼|EMR167.23+0.96 (+0.57%) ▲|FDX301.82-5.28 (-1.72%) ▼|GD354.55-0.34 (-0.10%) ▼|GE302.34+4.68 (+1.57%) ▲|GEV883.79-11.29 (-1.26%) ▼|GILD159.55+0.47 (+0.30%) ▲|GM81.30+0.76 (+0.94%) ▲|GOOG320.27+3.44 (+1.09%) ▲|GOOGL323.21+2.63 (+0.82%) ▲|GS921.54+9.77 (+1.07%) ▲|HD318.15-0.35 (-0.11%) ▼|HON219.63+0.82 (+0.37%) ▲|IBM251.93+1.68 (+0.67%) ▲|INTC94.37+0.63 (+0.67%) ▲|INTU328.74+0.29 (+0.09%) ▲|ISRG448.48+2.60 (+0.58%) ▲|JNJ271.63+2.90 (+1.08%) ▲|JPM339.54+3.75 (+1.12%) ▲|KO91.71+0.53 (+0.58%) ▲|LIN508.71+0.06 (+0.01%) ▲|LLY1,289.07+7.16 (+0.56%) ▲|LMT630.70+7.71 (+1.24%) ▲|LOW198.61+0.43 (+0.22%) ▲|LRCX253.16+12.31 (+5.11%) ▲|MA613.22+3.37 (+0.55%) ▲|MCD251.05+1.58 (+0.63%) ▲|MDLZ61.82-0.54 (-0.86%) ▼|MDT95.26+1.31 (+1.39%) ▲|META610.12-10.07 (-1.62%) ▼|MMM172.64+1.06 (+0.62%) ▲|MO73.21-0.28 (-0.38%) ▼|MRK140.47-1.35 (-0.95%) ▼|MS189.53+2.62 (+1.40%) ▲|MSFT526.45-4.88 (-0.92%) ▼|MU967.73+38.97 (+4.20%) ▲|NEE81.23-1.20 (-1.45%) ▼|NFLX61.60-0.93 (-1.48%) ▼|NKE37.24-0.33 (-0.87%) ▼|NOW149.79-5.00 (-3.23%) ▼|NVDA216.57-1.37 (-0.63%) ▼|ORCL129.61-0.93 (-0.71%) ▼|PEP132.65-0.85 (-0.64%) ▼|PFE29.31-0.49 (-1.64%) ▼|PG158.93-0.31 (-0.19%) ▼|PLTR193.43-5.31 (-2.67%) ▼|PM203.24+0.62 (+0.31%) ▲|QCOM180.64-3.53 (-1.92%) ▼|RTX197.45+2.85 (+1.46%) ▲|SBUX104.04+1.00 (+0.97%) ▲|SCHW88.30-1.00 (-1.12%) ▼|SO91.82-0.84 (-0.90%) ▼|SPG211.73-0.55 (-0.26%) ▼|T20.67-0.28 (-1.31%) ▼|TMO707.71+14.69 (+2.12%) ▲|TMUS145.50-1.33 (-0.91%) ▼|TSLA401.93-5.54 (-1.36%) ▼|TXN307.07-1.84 (-0.60%) ▼|UBER65.17-0.61 (-0.92%) ▼|UNH408.29-2.11 (-0.51%) ▼|UNP299.31-0.57 (-0.19%) ▼|UPS104.32-1.78 (-1.67%) ▼|USB59.35-0.39 (-0.65%) ▼|V402.18+0.32 (+0.08%) ▲|VZ43.19-0.75 (-1.70%) ▼|WFC83.94+1.28 (+1.55%) ▲|WMT119.15-0.18 (-0.15%) ▼|XOM182.72+2.81 (+1.56%) ▲|
13.7 C
New York
Wednesday, October 28, 2026

Tag: TRI SVY

newsFORsourcecompanycontentinformation1releasesmarket

Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific

SINGAPORE, July 22, 2025 /PRNewswire/ -- The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass...

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Construct including CT domain demonstrated higher levels of microdystrophin protein, increased muscle force, and improved resistance to damage in mice lacking dystrophin REGENXBIO's next-generation...

Diagnostics Transformed: $37 Billion Immunoassay Market Evolves with AI, Miniaturization, and POC Growth, reports Kalorama Information

ARLINGTON, Va., July 10, 2025 /PRNewswire/ -- Kalorama Information, a leading healthcare market intelligence firm, has published a comprehensive new report, Global Immunoassay Market:...

Nasal COVID Vax Shows Promise in Phase 1 Clinical Trial

CINCINNATI, July 4, 2025 /PRNewswire/ -- During the COVID-19 pandemic, scientists learned that the critical path to infection started with the SARS-CoV-2 virus invading...

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the...

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated...

Herbalife’s Aloin Identification Method for Aloe Vera Officially Recognized by AOAC INTERNATIONAL

Certified Method Enhances Global Botanical Quality and Safety BENGALURU, India, June 19, 2025 /PRNewswire/ -- Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced the...

Camurus’ POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients

CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findingsA follow-up Phase 3 study will be...

Shasqi Publishes Landmark Study in Clinical Cancer Research: First-in-Human Use of Click Chemistry Unlocks New Opportunities for Targeted Cancer Therapies

Shasqi is a leader in the translational application of click chemistry, a Nobel Prize winning technology, and the first company to use this technology in...

Discovery Suggests Method to Offset Antibiotic-Caused Harm to Infant Immune Systems

In mice, inosine supplement restored normal T cell development and enhanced infection resistance, according to study published in Cell. CINCINNATI, June 9, 2025 /PRNewswire/ --...

The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC

CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK) today announced that results from its registrational study (OptiTROP-Lung03) evaluating...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTRI SVY

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers